Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Prostatic Neoplasms × Lutetium-177 × Clear all

Phase

Status

Recruiting 4 Withdrawn 1 Terminated 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Metastatic Neuroendocrine Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Gastro-enteropancreatic neuroendocrine tumor 1 Biochemically Recurrent Prostate Carcinoma 1

Interventions

enzalutamide 29 Prednisone 26 Abiraterone Acetate 25 Radiotherapy 23 apalutamide 22 Magnetic Resonance Spectroscopy 22 Leuprolide 20 Androgen Antagonists 19 Radiosurgery 16 Gonadotropin-Releasing Hormone 15 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14 Docetaxel 14 darolutamide 13 pembrolizumab 12 Goserelin 12 bicalutamide 11 abiraterone 11 Radiation 10 Carboplatin 10 gallium 68 PSMA-11 9 Specimen Handling 9 Radiotherapy, Intensity-Modulated 9 Triptorelin Pamoate 8 Brachytherapy 8 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 8 relugolix 7 olaparib 7 luprolide acetate gel depot 7 cabazitaxel 7 Pluvicto 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05849298 2026-03-03

PSMACare

Novartis

Phase 2 Active not recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡